Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ❌ Debt failed
- ✅ P/E passed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 22.98%
Price change 2019 → 2020: -21.69%
Price change 2020 → 2021: 19.84%
Price change 2021 → 2022: -20.32%
Price change 2022 → 2023: 5.46%
Price change 2023 → 2024: -8.74%
Price change 2024 → 2025: 45.00%
Price change 2025 → 2026: -3.70%
Price change 2026 (year to date): -4.85%
Financial growth
Revenue CAGR (8 years): 0.83%
Earnings CAGR (8 years): 6.73%
Growth status: positive trend (>1%/yr) in revenue OR earnings, but not both.
Debt
Debt-to-equity ratio: 1.08
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 10.16
P/E < 25.0 (maximum threshold).
Correction (6 months)
Current correction: 20.20% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="GSK" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| GSK plc | 11.0 | 1.08 | +0.9 % | 🔒 |
| Sanofi | 8.8 | 0.28 | +2.5 % | – |
| EssilorLuxottica S.A. | 33.6 | 0.37 | +14.2 % | – |
| Moderna, Inc. | – | 0.22 | +37.8 % | – |
| Pfizer Inc. | 9.8 | 0.78 | −0.5 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|